|
Name |
Altertenuol
|
Molecular Formula | C14H10O6 | |
IUPAC Name* |
2,3,7-trihydroxy-9-methoxybenzo[c]chromen-6-one
|
|
SMILES |
COC1=CC2=C(C(=C1)O)C(=O)OC3=CC(=C(C=C32)O)O
|
|
InChI |
InChI=1S/C14H10O6/c1-19-6-2-8-7-4-9(15)10(16)5-12(7)20-14(18)13(8)11(17)3-6/h2-5,15-17H,1H3
|
|
InChIKey |
CBQSPNLMOXKZHJ-UHFFFAOYSA-N
|
|
Synonyms |
Altertenuol; Altenuisol-; Altertenuol-; JG3R2QMK6X; 1188382-26-4; 2,3,7-Trihydroxy-9-methoxy-6H-benzo(C)chromen-6-one; 2,3,7-Trihydroxy-9-methoxy-6H-benzo[c]chromen-6-one; 6H-Dibenzo(b,d)pyran-6-one, 2,3,7-trihydroxy-9-methoxy-; UNII-JG3R2QMK6X; CHEMBL593328; dehydroaltenusin derivative, 26; BDBM33391; 2,3,7-trihydroxy-9-methoxydibenzo[b,d]pyran-6-one
|
|
CAS | 1188382-26-4 | |
PubChem CID | 44246316 | |
ChEMBL ID | CHEMBL593328 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 274.22 | ALogp: | 2.5 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.358 |
Caco-2 Permeability: | -5.049 | MDCK Permeability: | 0.00000743 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.933 |
Human Intestinal Absorption (HIA): | 0.096 | 20% Bioavailability (F20%): | 0.147 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.01 | Plasma Protein Binding (PPB): | 92.96% |
Volume Distribution (VD): | 0.647 | Fu: | 11.57% |
CYP1A2-inhibitor: | 0.981 | CYP1A2-substrate: | 0.888 |
CYP2C19-inhibitor: | 0.058 | CYP2C19-substrate: | 0.06 |
CYP2C9-inhibitor: | 0.478 | CYP2C9-substrate: | 0.903 |
CYP2D6-inhibitor: | 0.519 | CYP2D6-substrate: | 0.713 |
CYP3A4-inhibitor: | 0.219 | CYP3A4-substrate: | 0.081 |
Clearance (CL): | 9.77 | Half-life (T1/2): | 0.814 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.169 |
Drug-inuced Liver Injury (DILI): | 0.974 | AMES Toxicity: | 0.48 |
Rat Oral Acute Toxicity: | 0.051 | Maximum Recommended Daily Dose: | 0.925 |
Skin Sensitization: | 0.946 | Carcinogencity: | 0.031 |
Eye Corrosion: | 0.067 | Eye Irritation: | 0.95 |
Respiratory Toxicity: | 0.182 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005360 | 1.000 | D04AIT | 0.430 | ||||
ENC004389 | 0.754 | D0K8KX | 0.402 | ||||
ENC005361 | 0.719 | D07MGA | 0.349 | ||||
ENC001773 | 0.719 | D06GCK | 0.348 | ||||
ENC001653 | 0.642 | D0AZ8C | 0.264 | ||||
ENC005808 | 0.642 | D0U3YB | 0.264 | ||||
ENC005191 | 0.642 | D02TJS | 0.260 | ||||
ENC004846 | 0.642 | D0G4KG | 0.256 | ||||
ENC002692 | 0.623 | D0G5UB | 0.250 | ||||
ENC002516 | 0.600 | D0FA2O | 0.244 |